Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Receivables (2016 - 2025)

Standard Biotools (LAB) has disclosed Receivables for 16 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 6.96% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, down 6.96% year-over-year, with the annual reading at $13.7 million for FY2025, 6.96% down from the prior year.
  • Receivables for Q4 2025 was $13.7 million at Standard Biotools, down from $13.9 million in the prior quarter.
  • The five-year high for Receivables was $36.0 million in Q1 2024, with the low at $10.9 million in Q2 2022.
  • Average Receivables over 5 years is $19.6 million, with a median of $16.9 million recorded in 2022.
  • The sharpest move saw Receivables surged 148.29% in 2024, then plummeted 60.55% in 2025.
  • Over 5 years, Receivables stood at $18.3 million in 2021, then fell by 5.68% to $17.3 million in 2022, then grew by 15.58% to $20.0 million in 2023, then dropped by 26.19% to $14.7 million in 2024, then decreased by 6.96% to $13.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $13.7 million, $13.9 million, and $14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.